Study of Human Antimicrobial Peptides Active Against Some Bacteroidota Species of the Oral Cavity

The increasing problem of antibiotic resistance is a critical global health issue, necessi‑
tating the development of alternative therapeutic strategies to manage infections effec‑
tively. Among the promising solutions are human antimicrobial peptides (AMPs), natu‑
rally occurring molecules known for their broad spectrum of antimicrobial activity. Back‑
ground/Objectives: This study investigates the potential of some AMPs, selected through
a bioinformatic approach, as alternatives to conventional antibiotics, particularly focusing
on their efficacy against species within the Bacteroidota phylum. These species, including
pathogens such as Porphyromonas gingivalis, Capnocytophaga ochracea, and Capnocytophaga
canimorsus, are well known for their roles in various human infections and related diseases.
Non‑pathogenic environmental species, such as Flavobacterium johnsoniae, are also included
in this group, frequently used as a model organism. Methods: By analyzing the antimi‑
crobial efficacy, mechanisms of action, and potential therapeutic applications of human
AMPs, this research underscores their significance in addressing the challenge of antibi‑
otic resistance. Results: This study identified three peptides, KTL24, LIR23, and MFP22, as
particularly interesting. These peptides are derived from specific human proteins, namely
SPI1, NAPSA and SCUB1. Conclusions: Their notable antimicrobial potential suggests
that AMPs could serve either as a complementary treatment alongside traditional antibi‑
otics or as a standalone therapy, mitigating the ongoing spread of antibiotic resistance and
offering an alternative in global health strategies